

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Brii Biosciences Limited
腾盛博药生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2137)

VOLUNTARY ANNOUNCEMENT
APPOINTMENT OF CHIEF SCIENTIFIC OFFICER

This announcement is made by the board of directors (the “**Board**”) of Brii Biosciences Limited (the “**Company**”) on a voluntary basis.

The Board is pleased to announce the appointment of Dr. Brian Alvin Johns (“**Dr. Johns**”), Ph.D., as the Chief Scientific Officer of the Company, with effect from January 3, 2024. Dr. Johns will oversee the discovery programs at the Company and set the Company’s future pipeline strategy and priority.

Dr. Johns brings a wealth of experience from the pharmaceutical industry, with a proven track record of successfully building and leading teams in the discovery and early development of novel medicines. His deep understanding of end-to-end research and development objectives has played a pivotal role in creating and delivering differentiated medicines that have transformed many patients’ lives.

“I am thrilled to reunite with Dr. Johns as our Chief Scientific Officer,” said Dr. Zhi Hong, Ph.D., the Chairman and the Chief Executive Officer of the Company. “His accomplishment as a medicine discovery leader was second to none. His unique experience working in big pharma and start-up biotech will serve the Company very well.”

Prior to joining the Company, Dr. Johns served as the Chief Scientific Officer at HemoShear Therapeutics, Inc., where he led his team to novel targets and platforms in various disease areas. Before that, he was the vice president of discovery at ViiV Healthcare Limited (“**ViiV**”) and GlaxoSmithKline plc. (“**GSK**”), where he made huge contributions to ViiV/GSK’s human immunodeficiency virus franchise with the discovery of groundbreaking medications in dolutegravir and cabotegravir.

Dr. Johns holds a Ph.D. in Chemistry and has received numerous honors and awards for his substantial contributions to the field. His extensive expertise in medicinal chemistry and drug discovery is further highlighted by numerous patents and publications.

“I am excited to join the Company and contribute to the development of transformative therapies against infectious diseases,” said Dr. Johns. “The Company has a strong focus on curative medicines, novel treatment options and a highly respected dream team, and I can’t wait to be a member of the team that will advance the mission of addressing major public health issues with breakthrough innovation and insight.”

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, January 3, 2024

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Dr. Ankang Li as executive directors; Mr. Robert Taylor Nelsen as non-executive director; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive directors.